<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atypical antidepressants: Pharmacology, administration, and side effects</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atypical antidepressants: Pharmacology, administration, and side effects</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Atypical antidepressants: Pharmacology, administration, and side effects</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Hirsch, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert J Birnbaum, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Roy-Byrne, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H20531374"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Advances in understanding brain neurophysiology have led to the development of atypical antidepressants, including [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Agomelatine (not available in the United States)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">Mirtazapine</a></p><p></p><p>The atypical antidepressants are distinct from other classes of antidepressants that include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors, serotonin modulators, tricyclics, and monoamine oxidase inhibitors. Atypical antidepressants are frequently used in patients with major depression who have inadequate responses or intolerable side effects during first-line treatment with SSRIs [<a href="#rid2">2</a>]. However, atypical antidepressants are often first-line treatment if the drug has a desirable characteristic (eg, sexual side effects and weight gain occur less often with <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> than SSRIs).</p><p>The pharmacology, administration, and side effects of atypical antidepressants are reviewed here. Choosing a regimen for the initial treatment of depression and treatment of resistant depression is discussed separately, as are other antidepressant drug classes:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1713.html" rel="external">"Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/86265.html" rel="external">"Serotonin modulators: Pharmacology, administration, and side effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">"Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">"Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><span class="utd-adt-cnt utd-adt-pathwys utd-content-138287">(Related Pathway(s):  <a class="utd-content-138287" href="/pathway/138287?topicRef=85816&amp;source=see_link">Unipolar major depression: Initial pharmacologic therapy in adults</a>.)</span></p><p></p><p class="headingAnchor" id="H20533483"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H28673666"><span class="h2">Drug-drug interactions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> may inhibit hepatic cytochrome P4502D6 enzymes that metabolize other medications and thereby cause drug-drug interactions [<a href="#rid3">3</a>]. By contrast, agomelatine and <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> do not moderately or potently inhibit P450 enzymes, and may thus be of benefit to depressed patients who are receiving other medications for general medical conditions. Specific interactions of atypical antidepressants with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p class="headingAnchor" id="H20533490"><span class="h2">Guidelines to review with patients</span><span class="headingEndMark"> — </span>Prior to prescribing atypical antidepressants, clinicians should discuss:</p><p class="bulletIndent1"><span class="glyph">●</span>Drug interactions</p><p class="bulletIndent1"><span class="glyph">●</span>Side effects</p><p class="bulletIndent1"><span class="glyph">●</span>Time to response</p><p class="bulletIndent1"><span class="glyph">●</span>Stopping the medication</p><p></p><p>Common and serious side effects and the need to take the medication as prescribed rather than on an as needed basis should be reviewed. Patients should also be informed that although some response may occur within the first two weeks of treatment, it may take many weeks (eg, 8 to 14) for a full response (severity of illness and comorbid disease may affect how quickly depressed patients respond to treatment) [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H20533497"><span class="h2">Medical tests and plasma levels</span><span class="headingEndMark"> — </span>No specific medical tests are required before starting atypical antidepressants. However, clinicians who prescribe agomelatine and wish to comply with recommendations from the European Medicines Agency should check liver function tests at baseline prior to initiating treatment, and then after 6, 12, and 24 weeks of treatment.</p><p>Atypical antidepressant serum concentrations are not routinely monitored because they have not been shown to correlate with clinical response [<a href="#rid5">5</a>]. However, levels can assess adherence and whether unresponsive patients are rapid metabolizers. Levels can also establish that it is safe to begin another serotonergic drug (eg, a monoamine oxidase inhibitor) after discontinuing an antidepressant that has serotonergic properties (eg, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>), in order to avoid the serotonin syndrome  (<a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p class="headingAnchor" id="H20533511"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>We suggest starting with the lowest minimal effective dose in order to avoid side effects and slowly increasing the dose as needed. Starting doses and target dose ranges of each atypical antidepressant are listed in the table  (<a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">table 2</a>). Depressed patients with comorbid anxiety disorders may tolerate the medication better by starting with half of the suggested dose. Doses are adjusted according to patient response, tolerability, and clinical urgency.</p><p>Finding the effective dose of an antidepressant involves trial and error. After starting the drug and titrating up to the minimum effective dose, response should be monitored over the next two to four weeks. For patients who tolerate the antidepressant but do not respond, we continue titrating up the dose slowly (to avoid side effects) every two to four weeks. For unresponsive patients who do not tolerate the drug, we suggest switching to a different antidepressant. (See  <a class="medical medical_review" href="/z/d/html/1716.html" rel="external">"Switching antidepressant medications in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment"</a> and  <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression", section on 'Next step treatment'</a>.)</p><p>Patients who recover from an episode of major depression should generally receive maintenance treatment with the full dose that successfully resolved the episode, rather than a lower dose. (See  <a class="medical medical_review" href="/z/d/html/14674.html" rel="external">"Unipolar depression in adults: Continuation and maintenance treatment", section on 'Dose'</a>.)</p><p class="headingAnchor" id="H85891814"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>Treatment of pregnant women with antidepressants is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1703.html" rel="external">"Severe antenatal unipolar major depression: Choosing treatment"</a>.)</p><p class="headingAnchor" id="H3491797"><span class="h2">Suicide</span><span class="headingEndMark"> — </span>The potential effect of atypical antidepressants on suicidal ideation and behavior in adults is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14672.html" rel="external">"Effect of antidepressants on suicide risk in adults"</a>.)</p><p class="headingAnchor" id="H20531439"><span class="h1">AGOMELATINE</span><span class="headingEndMark"> — </span>Agomelatine is used to treat major depression, but is contraindicated in patients with liver disease and patients taking medications that are potent inhibitors of the liver cytochrome P450 enzyme 1A2. The drug is not available in the United States.</p><p class="headingAnchor" id="H20533252"><span class="h2">Pharmacology</span><span class="headingEndMark"> — </span>Agomelatine is a bicyclic naphthalenic compound whose structure resembles that of melatonin [<a href="#rid6">6,7</a>]. Agomelatine acts as an agonist at melatonin receptors (MT1 and MT2) that are thought to provide beneficial effects upon sleep disturbances by helping to restore normal circadian rhythms [<a href="#rid8">8</a>]; patients with insomnia may thus prefer agomelatine [<a href="#rid8">8,9</a>]. The drug also antagonizes the serotonergic 5-HT2C receptor, which in turn enhances release of dopamine and norepinephrine. Agomelatine has no effect upon extracellular serotonin levels or monoamine uptake, and has no affinity for adrenergic, cholinergic, dopaminergic, and histaminergic receptors [<a href="#rid6">6,7,10</a>].</p><p>The pharmacokinetic parameters of agomelatine are displayed in the table  (<a class="graphic graphic_table graphicRef88061" href="/z/d/graphic/88061.html" rel="external">table 3</a>). Agomelatine is metabolized in the liver primarily by the P450 enzyme CYP1A2, and is contraindicated in patients taking medications that potently inhibit the enzyme. As an example, co-administration with <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">fluvoxamine</a> has been demonstrated in vivo to raise agomelatine serum concentrations 60-fold [<a href="#rid10">10</a>]. Specific interactions of agomelatine with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p>The serum concentration of agomelatine may be lowered in heavy smokers, via induction of CYP1A2.</p><p class="headingAnchor" id="H20533259"><span class="h2">Administration, dose, and discontinuation</span><span class="headingEndMark"> — </span>The usual starting dose of agomelatine for major depression is 25 mg per day at bedtime  (<a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">table 2</a>) [<a href="#rid5">5</a>]. For patients who do not respond after two to four weeks, the dose is increased to 50 mg per day.</p><p>Abrupt discontinuation of agomelatine 25 mg per day does not cause withdrawal symptoms. In a randomized trial, 88 patients with major depression who remitted during 12 weeks of treatment with agomelatine 25 mg per day were assigned to continue treatment or to placebo for two weeks; the number of discontinuation symptoms was comparable for the two groups [<a href="#rid11">11</a>]. However, for patients receiving agomelatine 50 mg per day, we suggest tapering the drug over one week, which is consistent with the preferred method of discontinuing any psychotropic medication.</p><p class="headingAnchor" id="H20533266"><span class="h2">Side effects</span><span class="headingEndMark"> — </span>Agomelatine may be hepatotoxic and is avoided in patients with active liver disease [<a href="#rid12">12</a>]. A pooled analysis of randomized trials found that elevation of serum transaminases &gt;3 times the upper limit of normal was greater for agomelatine 50 mg per day than placebo (1.3 versus 0.3 percent of patients) [<a href="#rid13">13</a>]. Thus, the European Medicines Agency requires liver function tests at baseline; after 6, 12, and 24 weeks of treatment; and when clinically indicated thereafter [<a href="#rid13">13</a>].</p><p>Other side effects are generally infrequent  (<a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">table 4</a>). In a pooled analysis of 13 randomized trials that compared agomelatine with placebo in 3034 patients with unipolar major depression, adverse effects that occurred more frequently with agomelatine included [<a href="#rid5">5,13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Dizziness – 6 percent of patients who received agomelatine</p><p class="bulletIndent1"><span class="glyph">●</span>Insomnia – 3 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Paresthesia – 1 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Blurred vision – 1 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Sinusitis – 1 percent</p><p></p><p>Based upon randomized trials, agomelatine does not cause weight gain, gastrointestinal distress, cardiovascular toxicity, or sexual impairment [<a href="#rid14">14</a>].</p><p>In addition, the tolerability of agomelatine may be superior to that of selective serotonin reuptake inhibitors (SSRIs) or <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>. A meta-analysis of nine randomized trials (3377 patients with major depression) compared agomelatine with SSRIs (<a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">escitalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, or <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>) and found that discontinuation of treatment due to side effects occurred less often with agomelatine (risk ratio 0.7, 95% CI 0.5-0.9) [<a href="#rid15">15</a>]. In addition, drop out due to side effects was less with agomelatine than venlafaxine (two trials, 608 patients; risk ratio 0.3, 95% CI 0.2-0.6).</p><p class="headingAnchor" id="H296927"><span class="h2">Overdose</span><span class="headingEndMark"> — </span>Case reports of patients who overdosed on agomelatine describe epigastralgia, somnolence, fatigue, agitation, anxiety, tension, dizziness, cyanosis, or malaise [<a href="#rid10">10</a>]. One patient ingested 2450 mg and recovered spontaneously.</p><p class="headingAnchor" id="H20531446"><span class="h1">BUPROPION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> is used to treat major depression, seasonal affective disorder, attention deficit hyperactivity disorder, tobacco dependence, hypoactive sexual disorder, and obesity [<a href="#rid16">16,17</a>].</p><p>Contraindications include bulimia nervosa, anorexia nervosa, use of monoamine oxidase inhibitors in the past two weeks, seizure disorders, and abrupt withdrawal from alcohol, benzodiazepines, or other sedatives. In addition, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> should be used cautiously in patients receiving other drugs that can lower seizure threshold. Additional information about drug-drug interactions are discussed elsewhere in this topic. (See <a class="local">'Drug-drug interactions'</a> above.)</p><p class="headingAnchor" id="H20533287"><span class="h2">Pharmacology</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> is a monocyclic aminoketone that is structurally related to amphetamine [<a href="#rid18">18</a>]. Some authorities classify the drug as a dopamine norepinephrine reuptake inhibitor, because it inhibits presynaptic reuptake of dopamine and norepinephrine (with a greater effect upon dopamine) [<a href="#rid1">1,19</a>]. The drug has little effect upon other neurotransmitters, and little to no affinity for postsynaptic receptors [<a href="#rid18">18,20</a>].</p><p>The pharmacokinetic parameters of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> are displayed in the table  (<a class="graphic graphic_table graphicRef88061" href="/z/d/graphic/88061.html" rel="external">table 3</a>). Bupropion is metabolized in the liver by the cytochrome P450 enzyme 2B6; medications that inhibit this enzyme may increase the plasma concentration of bupropion and thus raise the risk of seizure. Specific interactions of bupropion with other medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p class="headingAnchor" id="H20533294"><span class="h2">Administration, dose, and discontinuation</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> is available as three formulations that are bioequivalent and dosed as follows for major depression  (<a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">table 2</a>) [<a href="#rid16">16,18,21-23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immediate release</strong> – Typically started at 100 mg twice daily; for patients who do not respond after two to four weeks, the dose is increased to 100 mg three times daily. For patients who remain unresponsive after two to four weeks, the dose is increased to 150 mg three times daily. The maximum single dose is 150 mg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sustained release</strong> – Typically started at 150 mg once daily; for unresponsive patients who do not respond after two to four weeks, the dose is increased to 150 mg twice daily. For patients who remain unresponsive after two to four weeks, the dose is increased to 200 mg twice daily. The maximum single dose is 200 mg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extended release</strong> – Typically started at 150 mg once daily; for patients who do not respond after two to four weeks, the dose is increased to 300 mg once daily. For patients who remain unresponsive after two to four weeks, the dose is increased to 450 mg daily. The maximum single dose in the United States is 450 mg and in Europe is 300 mg per day. The extended release formulation is intended to be swallowed whole and not divided, crushed, or chewed.</p><p></p><p>In clinically urgent situations such as inpatient treatment, the dose of each formulation can be titrated up after three days. For patients with renal or hepatic impairment, we generally decrease the dose by at least 50 percent [<a href="#rid22">22</a>].</p><p>There appear to be no significant withdrawal symptoms upon discontinuation of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>. Nevertheless, we taper the drug over one to two weeks before stopping it, which is consistent with the preferred method of discontinuing any psychotropic medication.</p><p class="headingAnchor" id="H20533301"><span class="h2">Side effects</span><span class="headingEndMark"> — </span>Seizures may occur with <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> and the incidence appears to be correlated with dose. The rate with the [<a href="#rid16">16,23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Immediate release formulation at doses of 300 to 450 mg per day is 0.4 percent; however, the incidence increases approximately 10 fold at higher doses of up to 600 mg per day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sustained release formulation (which allows for lower peak plasma concentrations) at doses of 100 to 300 mg per day is 0.1 percent, and at 400 mg per day is 0.4 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extended release formulation at doses ≤450 mg per day is 0.1 percent.</p><p></p><p>By comparison, the estimated rate of seizures in patients treated with selective serotonin reuptake inhibitors (SSRIs) is 0.1 percent, tricyclics 0.4 to 2 percent, and in the general population is 0.07 to 0.09 percent [<a href="#rid24">24</a>]. Seizures appear to be especially problematic in patients with bulimia nervosa or anorexia nervosa, and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> is contraindicated in these patients; a randomized trial in which the drug was given to 55 nondepressed patients with bulimia nervosa found that generalized tonic-clonic seizures occurred in 4 (7 percent) [<a href="#rid25">25</a>].</p><p><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> can cause several other side effects  (<a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">table 4</a>). A pooled analysis of four randomized trials compared bupropion extended release (300 to 450 mg per day) with placebo in 991 patients with major depression for 8 or 12 weeks; adverse effects that occurred at least twice as often with bupropion than placebo included [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Dry mouth – 21 percent of patients who received <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a></p><p class="bulletIndent1"><span class="glyph">●</span>Nausea – 13 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Insomnia – 12 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Dizziness – 10 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety – 6 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspepsia – 6 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Sinusitis – 5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Tremor – 5 percent</p><p></p><p>The most common side effects (eg, dry mouth, nausea, and insomnia) of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> extended release are similar to those of the other two formulations [<a href="#rid17">17,27</a>]. However, the relative tolerability of the different formulations has not been directly compared.</p><p>Weight loss can occur with <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>. A meta-analysis found that patients lost approximately 1 kg [<a href="#rid28">28</a>]. As an example, an eight week randomized trial in 274 patients with unipolar major depression found that bupropion extended release (300 or 450 mg per day) led to a mean weight loss of 1.1 kg, whereas placebo led to a mean weight increase of 0.2 kg [<a href="#rid29">29</a>].</p><p><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> may be preferred by patients who want to minimize the risk of antidepressant-induced sexual dysfunction. In addition, depressed patients with sexual dysfunction induced by SSRIs may find that adjunctive bupropion (300 mg per day) can improve desire and frequency of sexual activity. The use of bupropion monotherapy to avoid sexual side effects, and augmentation of SSRIs with bupropion to relieve sexual side effects, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1706.html" rel="external">"Sexual dysfunction caused by selective serotonin reuptake inhibitors (SSRIs): Management"</a>.)</p><p>Patients may notice <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> is mildly stimulating, which may be interpreted as anxiety and can lead to insomnia if given shortly before bedtime. This stimulant-like effect may be beneficial in depressed patients with fatigue, hypersomnia, or poor concentration [<a href="#rid23">23</a>]. A retrospective study of administrative claims data suggests that the drug’s stimulating effects may possibly lead to diversion and misuse [<a href="#rid30">30</a>]; however, the low quality of this evidence leads us to suggest that clinicians should generally not change their practice with regard to using bupropion.</p><p>Although some studies indicate that <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> has minimal effects upon blood pressure [<a href="#rid29">29,31</a>], other studies suggest that it may raise blood pressure, especially if it is used in conjunction with the transdermal nicotine patch [<a href="#rid32">32</a>].</p><p>For many drugs, side effects are associated with peak plasma concentrations [<a href="#rid16">16</a>]. The once daily extended release and twice daily sustained release formulations of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> reduce the number of exposures to peak concentrations, compared with the thrice daily immediate release formulation. Discontinuation of treatment due to side effects in randomized trials was greater for bupropion sustained release than placebo, and comparable for extended release and placebo:</p><p class="bulletIndent1"><span class="glyph">●</span>In a pooled analysis of three trials that compared <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> sustained release (100 to 400 mg per day) with placebo for eight weeks in 1420 patients with major depression, discontinuation of treatment due to side effects occurred in more patients who received bupropion than placebo (7 versus 4 percent) [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A pooled analysis of five randomized trials that compared <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> extended release (150 to 450 mg per day) with placebo for eight weeks in 1597 patients with major depression found that discontinuation of treatment due to side effects was comparable with bupropion and placebo (5 versus 4 percent) [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H296934"><span class="h2">Overdose</span><span class="headingEndMark"> — </span>Overdose of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> can cause seizures, hypertension, tachycardia, arrhythmias, and death. (See  <a class="medical medical_review" href="/z/d/html/15239.html" rel="external">"Acute poisoning from atypical (non-SSRI) antidepressants, including serotonin modulators and serotonin-norepinephrine reuptake inhibitors (SNRIs)", section on 'Bupropion'</a>.)</p><p class="headingAnchor" id="H20531453"><span class="h1">MIRTAZAPINE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">Mirtazapine</a> is used to treat major depression, generalized anxiety disorder, and tension type headaches.</p><p class="headingAnchor" id="H20533322"><span class="h2">Pharmacology</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">Mirtazapine</a> is a piperazinoazepine compound that has a tetracyclic structure [<a href="#rid33">33,34</a>]. However, the drug is not related to the tetracyclic antidepressant <a class="drug drug_general" data-topicid="9588" href="/z/d/drug information/9588.html" rel="external">maprotiline</a>, which is classified with the tricyclic antidepressants because it blocks reuptake of serotonin and norepinephrine. By contrast, mirtazapine is not a reuptake inhibitor, and some authorities classify mirtazapine as a noradrenergic and specific serotonergic antidepressant because it antagonizes presynaptic alpha-2 adrenergic receptors and postsynaptic serotonin 5-HT2 and serotonin 5-HT3 receptors. Blockade of the adrenergic receptors increases release of norepinephrine and serotonin. Blockade of the serotonergic receptors increases neurotransmission mediated by serotonin 5-HT1 receptors. In addition, mirtazapine has a high affinity for histamine H1 receptors (which probably accounts for the drug’s sedative properties). Mirtazapine has low affinity for cholinergic, alpha-1 adrenergic, and dopaminergic receptors.</p><p>The pharmacokinetic parameters of <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> are displayed in the table  (<a class="graphic graphic_table graphicRef88061" href="/z/d/graphic/88061.html" rel="external">table 3</a>). Drug-drug interactions with mirtazapine are generally not a problem because the drug is not a potent or moderate inhibitor of hepatic cytochrome P450 enzymes [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H20533329"><span class="h2">Administration, dose, and discontinuation</span><span class="headingEndMark"> — </span>The usual starting dose of <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> for major depression is 15 mg at bedtime  (<a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">table 2</a>). For patients who do not respond after two to four weeks, the dose is increased to 30 mg at bedtime. For patients who remain depressed after two to four weeks, the dose is increased to 45 mg at bedtime; some patients may require another increase to 60 mg [<a href="#rid35">35</a>]. The dose can be titrated up more quickly in clinically urgent situations (eg, inpatient treatment), by 15 mg increments every week. For patients with severe renal (creatinine clearance &lt;40 mL/minute) or hepatic impairment, we generally limit the dose to 30 mg per day due to decreased clearance of the drug [<a href="#rid34">34</a>].</p><p>The relationship between the dose and side effects of <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> is unusual, in that sedation appears more pronounced at doses of 15 mg daily than at doses ≥30 mg daily; this may be due to increased noradrenergic neurotransmission as the dose is increased [<a href="#rid34">34</a>]. Dosing may be initiated at 30 mg or more in order to reduce sedation. It is not clear whether side effects other than sedation are reduced at higher doses (30 or 45 mg per day).</p><p>The drug is available as an oral, rapidly dissolving tablet, which can be useful for patients with swallowing difficulties and gastrointestinal disorders [<a href="#rid33">33</a>].</p><p>Abrupt discontinuation of <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> can cause discontinuation symptoms. Information about preventing the discontinuation syndrome is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/105323.html" rel="external">"Discontinuing antidepressant medications in adults", section on 'Atypical antidepressants'</a>.)</p><p class="headingAnchor" id="H20533336"><span class="h2">Side effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">Mirtazapine</a> can cause several side effects  (<a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">table 4</a>). A pooled analysis of randomized trials that compared mirtazapine with placebo for six weeks in 814 patients with major depression found that discontinuation of treatment due to side effects for mirtazapine was 16 percent and for placebo 7 percent [<a href="#rid33">33,36</a>].</p><p>The frequency of specific side effects was examined in a pooled analysis of randomized trials that included 1726 patients with major depression; adverse effects that occurred more frequently with <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> than placebo included [<a href="#rid37">37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Dry mouth – 25 percent of patients who received <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a></p><p class="bulletIndent1"><span class="glyph">●</span>Drowsiness – 23 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Sedation – 19 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Appetite increased – 11 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Weight increased – 10 percent</p><p></p><p>Sexual dysfunction with <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> and placebo appear to be comparable, based upon a meta-analysis [<a href="#rid38">38</a>]. In addition, changes in blood pressure and pulse are comparable for mirtazapine and placebo, based upon a pooled analysis of randomized patients with major depression [<a href="#rid37">37</a>].</p><p><a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">Mirtazapine</a> may possibly cause agranulocytosis and neutropenia in rare instances [<a href="#rid33">33,37</a>]. However, we do not routinely monitor white blood cell counts.</p><p class="headingAnchor" id="H296941"><span class="h2">Overdose</span><span class="headingEndMark"> — </span>Overdose of <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> is often benign. (See  <a class="medical medical_review" href="/z/d/html/15239.html" rel="external">"Acute poisoning from atypical (non-SSRI) antidepressants, including serotonin modulators and serotonin-norepinephrine reuptake inhibitors (SNRIs)", section on 'Mirtazapine'</a>.)</p><p class="headingAnchor" id="H20531538"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/4866.html" rel="external">"Patient education: Depression treatment options for adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/4868.html" rel="external">"Patient education: Depression in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">"Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"</a>)</p><p></p><p>The National Institute of Mental Health also has educational material on the use of antidepressants, including SSRIs, entitled, "What medications are used to treat depression?" that is available online at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Ftopics%2Fmental-health-medications&amp;token=DUyqmXMqVzfwMQwHS0hGhjVnvSmWNYwrVIOQjil9H1c7QeKzCSx0qXlroHThkaY5AZSlsPjqMvW2SrhzIcY0ie182z2bJyFkd3seZ7M6%2Fa0%3D&amp;TOPIC_ID=85816" target="_blank">the website</a>. Material explaining the symptoms, causes, and treatment for depression is also available in a booklet entitled "Depression" that is available online at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Fpublications%2Fdepression&amp;token=lblfowwGB6QwC91WNuiIf4ajjCUnrtrjbsV3PkfR7znk0D5d%2Fr0ErMPgiqIitkwYLP%2FHA1tFvsLfSIGbbHxrmA%3D%3D&amp;TOPIC_ID=85816" target="_blank">the website</a>. Both publications can also be obtained through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.</p><p>The Depression and Bipolar Support Alliance (available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dbsalliance.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rC6dBWU8%2FMZEcwGeeAm5c58EpMgcvhu2s4%2FQc68YQejm&amp;TOPIC_ID=85816" target="_blank">the website</a> or 800-826-3632) is a national organization whose mission is to educate members about depression and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.</p><p>The National Alliance on Mental Illness (available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nami.org%2FHome&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F8kABYN690CzsdrTBuRq2QekIBbQQeqX70Vmx%2B0z8d0m&amp;TOPIC_ID=85816" target="_blank">the website</a> or 800-950-6264) is a similarly structured organization devoted to providing education, support, and advocacy for patients with any mental illness. Depression is one of their priorities.</p><p class="headingAnchor" id="H20531545"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific drugs and their indications</strong> – Atypical antidepressants include agomelatine, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, and <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a>. These drugs can be used for the initial treatment of major depression, as well as patients with treatment-resistant depression or other disorders. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">"Unipolar major depression in adults: Choosing initial treatment"</a> and  <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">"Unipolar depression in adults: Choosing treatment for resistant depression"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-drug interactions </strong>– <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> may inhibit hepatic cytochrome CYP2D6 enzymes that metabolize other medications and thereby cause drug-drug interactions. By contrast, agomelatine and <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> do not moderately or potently inhibit P450 enzymes. (See <a class="local">'Drug-drug interactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guidelines to review with patients</strong> – Prior to prescribing atypical antidepressants, clinicians should discuss drug interactions, side effects  (<a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">table 4</a>), time to response, and stopping the medication. No specific medical tests are required before starting atypical antidepressants and drug plasma levels are not routinely performed. (See <a class="local">'Guidelines to review with patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – We suggest starting with a low dose to avoid side effects, and increasing the dose slowly. Starting doses and target dose ranges of each atypical antidepressant are listed in the table  (<a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">table 2</a>). (See <a class="local">'Dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Agomelatine</strong> – Agomelatine is contraindicated in patients with liver disease and patients taking medications that are potent inhibitors of the liver cytochrome P450 enzyme 1A2. Adverse effects include dizziness. The drug is not available in the United States. (See <a class="local">'Agomelatine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bupropion</strong> – Adverse effects of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> include seizures, dry mouth, nausea, insomnia, dizziness, anxiety, dyspepsia, sinusitis, and tremor. (See <a class="local">'Bupropion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mirtazapine</strong> – Adverse effects of <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> include dry mouth, drowsiness, sedation, appetite increase, and weight increase. (See <a class="local">'Mirtazapine'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998; 51:237.</a></li><li><a class="nounderline abstract_t">Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354:1231.</a></li><li class="breakAll">Wynn GH, Sandson N, Muniz J. Psychiatry. In: Clinical Manual of Drug Interaction Principles for Medical Practice, Wynn GH, Oesterheld JR, Cozza KL, Armstrong SC (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.423.</li><li><a class="nounderline abstract_t">Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519.</a></li><li><a class="nounderline abstract_t">McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol 2010; 25:95.</a></li><li><a class="nounderline abstract_t">Green B. Focus on agomelatine. Curr Med Res Opin 2011; 27:745.</a></li><li><a class="nounderline abstract_t">Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011; 378:621.</a></li><li><a class="nounderline abstract_t">Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010; 71:109.</a></li><li><a class="nounderline abstract_t">Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68:1723.</a></li><li class="breakAll">Electronic medicines compendium. http://www.medicines.org.uk/ (Accessed on July 31, 2012).</li><li><a class="nounderline abstract_t">Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19:271.</a></li><li><a class="nounderline abstract_t">Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf 2011; 34:709.</a></li><li class="breakAll">European Medicines Agency. CHMP Assessment report for Valdoxan. http://www.ema.europa.eu/ (Accessed on July 31, 2012).</li><li><a class="nounderline abstract_t">Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010; 24:479.</a></li><li><a class="nounderline abstract_t">Guaiana G, Gupta S, Chiodo D, et al. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev 2013; :CD008851.</a></li><li><a class="nounderline abstract_t">Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005; 7:106.</a></li><li class="breakAll">Hamilton DV, Clayton AH. Bupropion. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.495.</li><li class="breakAll">Labbate LA, Fava M, Rosenbaum JF, Arana GW. Drugs for the treatment of depression. In: Handbook of Psychiatric Drug Therapy, Sixth Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.54.</li><li><a class="nounderline abstract_t">Dhillon S, Yang LP, Curran MP. Spotlight on bupropion in major depressive disorder. CNS Drugs 2008; 22:613.</a></li><li class="breakAll">Janicak PG, Marder SR, Pavuluri MN. Treatment with antidepressants. In: Principles and Practice of Psychopharmacotherapy, Fifth Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.199.</li><li><a class="nounderline abstract_t">Gartlehner G, Thaler K, Hill S, Hansen RA. How should primary care doctors select which antidepressants to administer? Curr Psychiatry Rep 2012; 14:360.</a></li><li><a class="nounderline abstract_t">Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 2005; 27:1685.</a></li><li><a class="nounderline abstract_t">Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs 2008; 68:653.</a></li><li><a class="nounderline abstract_t">Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract 2005; 59:1435.</a></li><li><a class="nounderline abstract_t">Horne RL, Ferguson JM, Pope HG Jr, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988; 49:262.</a></li><li class="breakAll">Clayton AH, Gillespie EH. Bupropion. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.415.</li><li><a class="nounderline abstract_t">Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 1999; 21:454.</a></li><li><a class="nounderline abstract_t">Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71:1259.</a></li><li><a class="nounderline abstract_t">Jefferson JW, Rush AJ, Nelson JC, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67:865.</a></li><li><a class="nounderline abstract_t">Steele LS, Macdonald EM, Gomes T, et al. Rates of Anomalous Bupropion Prescriptions in Ontario, Canada. Ann Fam Med 2015; 13:343.</a></li><li><a class="nounderline abstract_t">Thase ME, Haight BR, Johnson MC, et al. A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol 2008; 28:302.</a></li><li class="breakAll">Medication Guide for Bupropion approved by United States Food and Drug Administration. 12/2014 http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021515s029s030lbl.pdf (Accessed on January 16, 2015).</li><li><a class="nounderline abstract_t">Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs 2009; 23:427.</a></li><li class="breakAll">Schatzberg AF. Mirtazapine. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.429.</li><li class="breakAll">Macaluso M. Tricyclics, tetracyclics, and monoamine oxidase inhibitors. In: The American Psychiatric Association Publishing Textbook of Mood Disorders, Second Edition, Nemeroff CB, Rasgon N, Schatzberg AF, Strakowski SM (Eds), American Psychiatric Association Publishing, Washington, DC 2022. p.231.</li><li class="breakAll">Mirtazapine product information. http://www.merck.com/ (Accessed on August 01, 2012).</li><li><a class="nounderline abstract_t">Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10 Suppl 4:37.</a></li><li><a class="nounderline abstract_t">Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29:259.</a></li></ol></div><div id="topicVersionRevision">Topic 85816 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10333980" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16554525" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16554525" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16946176" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20196187" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The use of antidepressants in clinical practice: focus on agomelatine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21271795" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Focus on agomelatine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21596429" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Novel melatonin-based therapies: potential advances in the treatment of major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20193645" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18052566" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18052566" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15289700" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21830835" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A benefit-risk assessment of agomelatine in the treatment of major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21830835" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A benefit-risk assessment of agomelatine in the treatment of major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20192279" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24343836" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Agomelatine versus other antidepressive agents for major depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16027765" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16027765" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16027765" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18547129" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Spotlight on bupropion in major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18547129" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Spotlight on bupropion in major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22648236" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : How should primary care doctors select which antidepressants to administer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16368442" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18370448" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Bupropion: a review of its use in the management of major depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16351676" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Antidepressants and seizures: emphasis on newer agents and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3134343" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Treatment of bulimia with bupropion: a multicenter controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3134343" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treatment of bulimia with bupropion: a multicenter controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10321415" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Safety profile of sustained-release bupropion in depression: results of three clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21062615" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antidepressants and body weight: a comprehensive review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16848645" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26195679" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Rates of Anomalous Bupropion Prescriptions in Ontario, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18480687" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18480687" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453203" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mirtazapine: a review of its use in major depression and other psychiatric disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453203" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mirtazapine: a review of its use in major depression and other psychiatric disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453203" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mirtazapine: a review of its use in major depression and other psychiatric disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453203" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mirtazapine: a review of its use in major depression and other psychiatric disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8930008" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Safety of mirtazapine: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19440080" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
